Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Marathon Petroleum Corp (MPC) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Marathon Petroleum CorpTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Marathon Petroleum Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Marathon Petroleum Corp trades at $335.61 (market cap $89.95B). The key difference: Marathon Petroleum Corp is far larger — about 9.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Marathon Petroleum Corp pays a 1.25% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOMPC
Market Cap
$9.39B$89.95B
Sector
HealthEnergy
52-Week High
$354.54$320.32
52-Week Low
$241.71$158.59
Enterprise Value
$9.14B$116.48B
Dividend Yield
1.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Marathon Petroleum Corp

Marathon Petroleum (MPC) trades at $298.20, down 0.35% with a bearish technical signal despite strong fundamental performance. The stock shows exceptional earnings momentum with three consecutive quarterly beats, including a massive Q2 2026 EPS of $17.73 versus $14.27 expected. Valuation remains attractive with P/E of 10.34 and EV/EBITDA of 6.26, while maintaining robust profitability with 47.9% ROE.

MPC presents a compelling investment case with strong analyst support (76% buy ratings) and $330.70 price target upside. However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% pose fundamental concerns. Technical weakness near pivot point resistance at $297 requires monitoring despite positive refining margin outlook.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Marathon Petroleum Corp

Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.

Read more on MPC